According to the US Centers for Disease Control and Prevention (CDC), at least 2 million people in the United States become infected with bacteria that are resistant to antibiotics each year and at least 23,000 people die each year as a direct result of these infections. Many more people die from other conditions that were complicated by an antibiotic-resistant infection.
The rapid rise of multi-drug-resistant bacterial infections is a major global public health concern. Currently approved drugs are becoming increasingly ineffective and there are few new therapeutic agents in clinical development.
Watertown, Massachusetts-based Tetraphase Pharmaceuticals (TTPH) has the opportunity to meet this umet and urgent medical need.
Would an investment in Tetraphase make a lucrative...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: